Imagine this: a hospital conference room, lights low, filled with decision-makers. A sales representative clicks through slides driven by Palantir Technologies’ (NASDAQ:PLTR) Foundry platform, highlighting real-time data integration and pinpoint analytics that would make Pharma R&D from the past look like it’s still sending lab results by fax. Down the same hallway, Tempus AI (NASDAQ:TEM) is making its pitch: a genomics-driven diagnostics pipeline that has the potential to condense drug development months into weeks. Down the street, Recursion Pharmaceuticals (NASDAQ:RXRX), connected to Nvidia’s (NASDAQ:NVDA) AI muscle, is whipping up molecules more quickly than most of the major pharma companies can convene a patent meeting.
Track Palantir's stock moves here.
